|Awarded On||February 15, 2023|
|Title||Understanding and improving CAR T-cell therapy of T-ALL and LBL|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Maksim Mamonkin|
|Cancer Sites||Leukemia, Lymphoma|
It is estimated by the National Cancer Institute at NIH that in 2022 more than 23,000 people in the U.S. will die from leukemia. Recent development of immunotherapies, and especially chimeric antigen receptor (CAR)-modified cell therapies, have benefitted many patients with B-cell leukemia in which they can induce remissions and even cure the disease. Unfortunately, patients with T-cell leukemia do not have such options, owing to a number of difficulties in developing engineered cell therapies for this disease. In fact, there have been little progress in treating T-cell leukemia in the past two decades, and the patients still rely on chemotherapy and bone marrow transplants, which are very t...